Abstract
All had at least 2 determinations for postTx alloantibodies. Overall 229 samples were analyzed. Results: Twenty-two of 45 had preand/or postTx antiHLA-ab: 77% in A (17/22) and only 22% in B (5/23), p 0.0002. PreTx HLA-ab were present in 12 cases (27%): 8 class I II and 4 class I. Presensitization was more frequent in A (11/ 22 50%) than in B (1/ 23 4%, p 0.0005). Thirteen cases retained (8 cases) or developed (5 cases) antiHLA-ab during the 1st year postTx: 10 in A (50%) and 3 in B (13%), p 0.0008. Late after Tx ( 1year), antiHLA-ab were present in 8/18 (44%) in A and 3/22 (13.6%) in B (p 0.03). Eleven exhibited de novo antibodies at any time postTx (6 class I II, 4 class I and 1 class II): 7/22 in A (32%) and 4/23 in B (17%, p 0.0004). Four of 8 cases with CAD (50%) had preformed antiHLA-ab (3 retained postTx) compared to 8 of 37 without CAD (25.6%), small sample size for statistical analysis (p 0.09); none of CAD cases exhibited de novo antibodies. Conclusion: Preformed, persistent and de novo ELISA-detected antiHLA-ab were correlated with first-year acute rejection profile; further investigations with larger number of patients are needed to determine correlation with graft coronary disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
